References
- Lipocine announces $6million registered direct offering priced at-the-market. (2020). https://ir.lipocine.com/2020-02-25-Lipocine-Announces-6-Million-Registered-Direct-Offering-Priced-At-The-Market
- Lipocine streamlines its infringement lawsuit against Clarus Therapeutics. (2020). www.prnewswire.com/news-releases/lipocine-streamlines-its-infringement-lawsuit-against-clarus-therapeutics-301002214.html
- Nanoform establishes US subsidiary. (2020). www.prnewswire.com/news-releases/nanoform-establishes-us-subsidiary-301001701.html
- Valeritas announces agreement for Zealand Pharma to acquire business and retain employees. (2020). www.prnewswire.com/news-releases/valeritas-announces-agreement-for-zealand-pharma-to-acquire-business-and-retain-employees-301001626.html
- Luye Pharma grants Cipla Medpro exclusive distribution and marketing rights for Seroquel® and Seroquel XR® in South Africa and certain neighbouring countries. (2020). www.prnewswire.com/news-releases/luye-pharma-grants-cipla-medpro-exclusive-distribution-and-marketing-rights-for-seroquel-and-seroquel-xr-in-south-africa-and-certain-neighbouring-countries-301002366.html
- Elicio Therapeutics and Natera to collaborate in Phase I/II pancreatic cancer study of ELI-002. (2020). www.prnewswire.com/news-releases/elicio-therapeutics-and-natera-to-collaborate-in-phase-iii-pancreatic-cancer-study-of-eli-002-301002512.html
- Elicio Therapeutics and Natera to collaborate in Phase I/II pancreatic cancer study of ELI-002. (2020). https://elicio.com/2020/02/elicio-therapeutics-and-natera-to-collaborate-in-phase-i-ii-pancreatic-cancer-study-of-eli-002/
- Insulet partners with Abbott and Dexcom on automated insulin delivery. (2020). www.massdevice.com/insulet-partners-with-abbott-and-dexcom-on-automated-insulin-delivery/
- Dexcom and Insulet announce commercial agreement to integrate the Dexcom G6 and future G7 CGM into Insulet's Omnipod Horizon™ Automated Insulin Delivery System. (2020). https://investor.insulet.com/news-releases/news-release-details/dexcom-and-insulet-announce-commercial-agreement-integrate
- Dianomi Therapeutics exclusively licenses nucleic acid technologies from the Wisconsin Alumni Research Foundation (WARF). (2020). www.prnewswire.com/news-releases/dianomi-therapeutics-exclusively-licenses-nucleic-acid-technologies-from-the-wisconsin-alumni-research-foundation-warf-301002482.html
- m8 Pharmaceuticals and Vectans Pharma signed an exclusive licensing agreement of Loramyc® (miconazole Lauriad®) for Mexico and Brazil. (2020). www.prnewswire.com/news-releases/m8-pharmaceuticals-and-vectans-pharma-signed-an-exclusive-licensing-agreement-of-loramyc-miconazole-lauriad-for-mexico-and-brazil-301006249.html
- Flowonix receives FDA approval to market Prometra® II pump for use with intrathecal baclofen. (2020). www.prnewswire.com/news-releases/flowonix-receives-fda-approval-to-market-prometra-ii-pump-for-use-with-intrathecal-baclofen-301007586.html
- United Therapeutics and DEKA announce additional FDA clearance related to the unity subcutaneous delivery system for Remodulin®. (2020). www.prnewswire.com/news-releases/united-therapeutics-and-deka-announce-additional-fda-clearance-related-to-the-unity-subcutaneous-delivery-system-for-remodulin-301009770.html
- Halozyme announces FDA has accepted Biologics License Application for fixed-dose subcutaneous combination of Perjeta® and Herceptin® using Enhanze® technology. (2020). www.prnewswire.com/news-releases/halozyme-announces-fda-has-accepted-biologics-license-application-for-fixed-dose-subcutaneous-combination-of-perjeta-and-herceptin-using-enhanze-technology-301010295.html
- Crescita announces positive topline results from two pivotal Phase IIIclinical studies for its lead pipeline product in patients with plaque psoriasis. (2020). www.prnewswire.com/news-releases/crescita-announces-positive-topline-results-from-two-pivotal-phase-3-clinical-studies-for-its-lead-pipeline-product-in-patients-with-plaque-psoriasis-301002807.html
- Oramed reports positive results in the final cohort of its Phase IIb oral insulin trial. (2020). www.prnewswire.com/news-releases/oramed-reports-positive-results-in-the-final-cohort-of-its-phase-2b-oral-insulin-trial-301011661.html
- Renishaw announces completion of the main part of a multicentre clinical trial jointly undertaken with Herantis Pharma plc for the treatment of Parkinson’s disease patients. (2020). www.news-medical.net/news/20200226/Renishaw-Announces-Completion-of-the-Main-Part-of-a-Multi-Centre-Clinical-Trial-Jointly-Undertaken-with-Herantis-Pharma-plc-for-the-Treatment-of-Parkinsons-Disease-Patients.aspx
- Renishaw announces completion of the main part of a multicentre clinical trial. (2020). www.renishaw.com/en/renishaw-announces-completion-of-the-main-part-of-a-multi-centre-clinical-trial--45291
- 4D-printed microneedles for drug delivery and biosensing. (2020). www.europeanpharmaceuticalreview.com/news/112430/4d-printed-microneedles-for-drug-delivery-and-biosensing/
- Han Daehoon , MordeS Riddish , StefanoMarianiet al. 4D printing of a bioinspired microneedle array with backward-facing barbs for enhanced tissue adhesion. Adv. Funct. Mat. (2020). https://doi.org/10.1002/adfm.201909197
- Handheld 3D skin printer demonstrates accelerated healing of large, severe burns. (2020). https://news.engineering.utoronto.ca/handheld-3d-skin-printer-demonstrates-accelerated-healing-of-large-severe-burns/
- Could this handheld 3D bioink printer improve wound healing? (2020). www.drugdeliverybusiness.com/could-this-handheld-3d-bioink-printer-improve-wound-healing/
- Oil and hydrogel mix effective for precise dosing of medicine. (2020). www.europeanpharmaceuticalreview.com/news/113923/oil-and-hydrogel-mix-effective-for-precise-dosing-of-medicine/
- Wanzke Caren , Tena-SolsonaMarta , BenediktRieß , TebcharaniaLaura , BoekhovenJob. Active droplets in a hydrogel release drugs with a constant and tunable rate. Mater. Horiz.(2020). Advance Articlehttps://pubs.rsc.org/en/content/articlelanding/2020/MH/C9MH01822K#!divAbstract